The Metabolism of Intravenously Administered Iron‐Dextran

Abstract

Summary. A method is described for the separation of transferrin iron and iron‐dextran in plasma samples. Estimation of plasma levels following the intravenous administration of labelled iron‐dextran showed that the mean half clearance time was 5.9 hr. About 40% of the injected dose of iron in circulation was bound to transferrin 11 hr later and there was no difference between normal and iron deficient subjects in the rate of iron release by the reticuloendothelial system. The results indicate a need to re‐evaluate present concepts of reticuloendothelial iron metabolism.

Chelate-free metal ion binding and heat-induced radiolabeling of iron oxide nanoparticles

“…43 Overall, the PET/CT imaging and biodistribution data in mice are fully consistent with the known distribution of FH (and other USPIO nanoparticles) and with reported data on 89 Zr–DFO–FH. 15,25,31,37 …”

Physicochemical properties of ferumoxytol, a new intravenous iron preparation

“…Release of bioactive iron from intravenous iron preparations results mainly from intracellular release after clearance of the agent from plasma and uptake by reticuloendothelial cells [10–13]. However, several in vitro studies have shown evidence of iron‐induced biological activity, suggesting that release of bioactive or catalytic iron may occur before cellular uptake of the intact parenteral iron agent [14,15].…”

The anaemia of chronic disorders

“…Following the injection of 59Fe-dextran, the labelled dextran is cleared from the blood and over the next 16-20 hr 59Fe reappears in the plasma as 59Fe-transferrin (Kanakakorn, Cavill and Jacobs, 1973). Williams, Cavill and Kanakakor (1974) used this method to study RE iron release in the anaemia of RA and found no differences from normal subjects in the rate of clearance of the iron dextran, the proportion of the label which reappeared bound to transferrin, or the time taken to reach the peak 59Fe-transferrin activity, nor was there any difference in these parameters between anaemic and non-anaemic RA patients.…”